Pre-Seed Stage · Transplant & Beyond

Protecting the
Gift of Life — Without Compromise.

ImmuneShield Biotech is pioneering a Wharton's Jelly MSC secretome platform to transform transplant immunology — reducing rejection, sparing toxicity, and extending graft survival for the patients who need it most.

Request Investor Deck Our Platform
40K+
Transplants / year in US
30+
Years clinical expertise
$28B
Global immunosuppressant market
Who We Are

Built by Clinical Scientists.
Driven by Mission.

ImmuneShield Biotech was founded to address one of transplant medicine's most enduring challenges: the inability to prevent rejection without subjecting patients to the long-term harms of conventional immunosuppression.

Our approach is rooted in over three decades of frontline clinical experience in transplant immunology, combined with cutting-edge stem cell science and a deep commitment to patient outcomes.

"Every transplant represents a second chance at life. Our mission is to make sure that chance lasts."

Founded and led by a Starzl Transplant Institute–trained transplant immunologist, ImmuneShield is advancing a novel secretome-based immunomodulatory platform from the ground up — built not for financial engineering, but to save lives.

Leadership Team

Prakash Rao
Prakash Rao, PhD, MBA
Founder · Chief Executive Officer
Transplant immunologist with 30+ years of clinical experience, trained at the Thomas E. Starzl Transplant Institute. Visionary behind ImmuneShield's platform and therapeutic strategy.
Zbigniew Roger Mrowiec
Zbigniew "Roger" Mrowiec, PhD, CABP
Chief Scientific Officer
Pioneer in stem cell science and cryobiology with deep expertise in Wharton's Jelly MSC biology, secretome characterization, and advanced cell preservation technologies.
The Platform

A New Immunological
Paradigm for Transplantation

Our secretome-based platform harnesses the paracrine signaling power of Wharton's Jelly MSCs to modulate the immune response without the systemic toxicity of conventional drugs.

Wharton's Jelly MSC Secretome Platform

Unlike cell therapy approaches requiring live cell engraftment, ImmuneShield's acellular secretome formulation delivers a defined cocktail of immunomodulatory cytokines, extracellular vesicles, and growth factors — enabling scalable manufacturing and off-the-shelf deployment.

Step 01
Harvest & Characterize
WJ-MSCs isolated from ethically sourced umbilical cord tissue; secretome collected under defined culture conditions.
Step 02
Immune Modulation
Secretome suppresses pro-inflammatory T-cell activation while promoting regulatory T-cell expansion at the graft interface.
Step 03
Graft Protection
Anti-apoptotic and cytoprotective factors in the secretome reduce ischemia-reperfusion injury and chronic graft damage.
Step 04
Tolerance Induction
Long-term platform goal: induce operational tolerance, reducing or eliminating dependence on maintenance immunosuppression.
Transplant Immunology
Primary indication: preventing acute and chronic rejection in solid organ transplants. Renal, hepatic, and cardiac allograft protection.
Autoimmune Pipeline
Future applications in autoimmune disease states where immune dysregulation drives tissue injury — leveraging the same immunomodulatory platform.
Medical Device Protection
Secretome coating application for implantable devices to reduce foreign body response and prolong device functional longevity.
RNA Vaccine Adjuvant & CAR-T
Secretome-derived immunomodulatory factors as adjuvants to enhance RNA vaccine efficacy and reduce CAR-T cytokine storm — expanding the platform into next-generation cell and gene therapy.
Connect With Us

Ready to Learn More?

ImmuneShield Biotech is currently raising a pre-seed round to advance our lead platform program through IND-enabling studies. We welcome conversations with life science investors, strategic partners, and academic collaborators who share our commitment to transforming transplant outcomes.

Investor inquiries: invest@immuneshield-bio.tech
Dallas–Fort Worth, Texas, USA
Website: immuneshield-bio.tech